BioCardia Files 8-K Report
Ticker: BCDA · Form: 8-K · Filed: Jan 27, 2025 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Jan 27, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
TL;DR
BioCardia filed a routine 8-K, likely administrative or exhibit-related.
AI Summary
On January 27, 2025, BioCardia, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or material events were detailed in the provided text, suggesting it may be a routine filing or related to administrative matters.
Why It Matters
This filing indicates BioCardia, Inc. is fulfilling its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing appears to be a standard procedural 8-K without disclosure of significant new risks or material events.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- January 27, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 320 Soquel Way Sunnyvale, California 94085 (address) — Principal executive offices
FAQ
What specific "Other Events" are being reported by BioCardia, Inc. in this 8-K filing?
The provided text for the 8-K filing does not specify the details of the "Other Events" beyond listing it as an item information category.
What "Financial Statements and Exhibits" are included with this 8-K filing?
The filing lists "Financial Statements and Exhibits" as an item information category, but the specific contents are not detailed in the provided text.
What is the primary purpose of this 8-K filing for BioCardia, Inc. on January 27, 2025?
The filing is a Current Report Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934, indicating it's a mandatory disclosure for the company.
Has BioCardia, Inc. undergone any recent name changes according to this filing?
The filing indicates past name changes to Tiger X Medical, Inc. on 20110616, Cardo Medical, Inc. on 20081027, and CLICKNSETTLE COM INC on 20000823, but no recent name change is mentioned for the current report date.
What is BioCardia, Inc.'s Standard Industrial Classification (SIC) code?
BioCardia, Inc.'s Standard Industrial Classification (SIC) code is 2836, categorized under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2025-01-27 09:15:22
Key Financial Figures
- $0.001 B — h registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20250124_8k.htm (8-K) — 24KB
- ex_770363.htm (EX-99.1) — 10KB
- 0001437749-25-001886.txt ( ) — 166KB
- bcda-20250127.xsd (EX-101.SCH) — 3KB
- bcda-20250127_def.xml (EX-101.DEF) — 11KB
- bcda-20250127_lab.xml (EX-101.LAB) — 15KB
- bcda-20250127_pre.xml (EX-101.PRE) — 11KB
- bcda20250124_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 27, 2025, BioCardia, Inc. (the "Company") issued a press release announcing that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have been accepted for presentation in a late-breaking symposium at the American College of Cardiology 2025 Scientific Sessions, taking place in Chicago, March 29-31, 2025. A copy of the press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 BioCardia, Inc. press release dated January 27, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: January 27, 2025